Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Inclusion Criteria : * Participant is healthy, as determined by medical history and physical examination. * Participant is at least 13 years of age but not yet 22 years of age at time of enrollment. * For the Menactra® and Menomune® groups, participant received one dose of Menactra® or Menomune® in MTA02 trial and completed trial (2 blood samples, contacted for Month 6 safety follow up). * For the Control group, participant has no previous history of any meningococcal vaccination. * If \< 18 years of age, participant has signed Institutional Review Board (IRB) approved informed assent form and his/her parent/legal guardian has signed an IRB-approved informed consent form. * If ≥ 18 years of age, participant has signed an IRB-approved informed consent form. * Able to provide vaccination log. Exclusion Criteria : * Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc). * Known or suspected impairment of immunologic function. * Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 100.4ºF (≥ 38.0ºC) at the time of inclusion. * For the Menactra® and Menomune® groups, history of documented invasive meningococcal disease or previous meningococcal vaccination with the exception of meningococcal vaccination given as part of MTA02 trial. * For the Control group, history of documented invasive meningococcal disease or previous meningococcal vaccination. * Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. * Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn. * Received any vaccine in the 14-day period prior to study vaccination, or scheduled to receive any vaccination during the 14-day period after study vaccination. * Suspected or known hypersensitivity to any of the vaccine components. * Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures. * In females, a positive or equivocal urine pregnancy test at the time of vaccination. * Enrolled in another clinical trial. * Any condition, which, in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the vaccine.